Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 3, Issue 73, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3002138
Keywords
-
Categories
Funding
- NIH [R01 AR40072, R01 AR44076, 5 R01 AI075157, P30 AR053495]
- Rheuminations, Inc.
- Alliance for Lupus Research
Ask authors/readers for more resources
The autoimmune disease systemic lupus erythematosus (SLE) results from an inability of the immune system to discriminate between certain self-antigens and foreign ones. The most common treatment of SLE involves the use of immunosuppressive drugs to reduce inflammation, but these therapies have serious side effects. Three recent papers in Science Translational Medicine redirect focus on neutrophils, platelets, and interferon-a in the pathogenesis of SLE and reinforce the notion that researchers should seek to discover and devise combination therapies that target these processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available